Decitabine Market – Hypomethylating Agent Remains Central to...

agregó una foto Health

2026-09-02 06:46:25 -

Decitabine Market – Hypomethylating Agent Remains Central to Hematologic Malignancy Treatment

Market Overview The market for decitabine, a hypomethylating agent widely used in the treatment of myelodysplastic syndromes and acute myeloid leukemia, continues to hold clinical relevance even as newer targeted therapies enter oncology practice. Its mechanism of reactivating silenced tumor suppressor genes through DNA methylation inhibition has made it a mainstay in patients who are...

0 Commentarios 0 Acciones 5 Views 0 Vista previa